Literature DB >> 2887833

Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance.

C Clayberger, A Wright, L J Medeiros, T D Koller, M P Link, S D Smith, R A Warnke, A M Krensky.   

Abstract

During studies of T-cell recognition of autologous tumour cells, a number of tumour cell lines derived from patients with lymphoma proved to be poor stimulators of both autologous and allogeneic T-cell responses. Analysis of the tumour cell surface molecules indicated that expression of the lymphocyte-function-associated antigen, LFA-1, was lacking, whereas normal leucocytes from these patients expressed normal levels of LFA-1. Examination of other lymphoid tumours revealed that most high grade lymphomas, but not most low or intermediate grade lymphomas, do not express the LFA-1 molecule. Furthermore, in an initial survey, the tumours from 5 of 7 patients with non-relapsing large cell lymphomas expressed LFA-1 whereas only 3 of 18 patients with relapsing lymphomas had tumours that did so. These findings suggest that tumour cells lacking surface LFA-1 cannot initiate an effective immune response in vivo. This lack of immunogenicity might contribute to escape from immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887833     DOI: 10.1016/s0140-6736(87)92924-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Hodgkin's cells express a novel pattern of adhesion molecules.

Authors:  P A Ellis; D N Hart; B M Colls; J C Nimmo; J E MacDonald; H B Angus
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

Review 2.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  The promoter of the CD11b gene directs myeloid-specific and developmentally regulated expression.

Authors:  C S Shelley; M A Arnaout
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 4.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

5.  The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma.

Authors:  C M Spier; T M Grogan; S M Lippman; D J Slymen; J A Rybski; T P Miller
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

Review 6.  Biological significance of autologous tumor-killing activity and its induction therapy.

Authors:  A Uchida
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

Review 7.  New insights into tumor-host interactions in lymphoma metastasis.

Authors:  V Umansky; V Schirrmacher; M Rocha
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

8.  Adhesion receptor profile of thymic B-cell lymphoma.

Authors:  A Eichelmann; K Koretz; G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 9.  Cytotoxic T lymphocyte recognition of non-Hodgkin's B cell lymphomas.

Authors:  A M Krensky
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

10.  Anti-(human LFA-1) monoclonal antibodies bind P815 murine tumour cells.

Authors:  M J Palisson; A Altemeyer; I Moosbrugger; S Warter; G Hauptmann; P Bischoff
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.